The MYG1 Knockout CAL-27 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the MYG1 gene in the human CAL-27 oral squamous cell carcinoma cell line. This product offers a heterogeneous pool of cells with targeted gene disruption, enabling functional studies without the genetic homogeneity of single-cell-derived clones. The polyclonal format preserves the diversity of the originating population, making it suitable for bulk assays where population-level responses are evaluated.
The parental CAL-27 line is an epithelial cell model derived from a human tongue squamous cell carcinoma and carries a well-characterized mutation in the TP53 tumor suppressor gene. This p53-mutant background is permissive to survival and proliferation but also sensitizes cells to mitochondrial insults, as p53 regulates mitochondrial function and apoptosis. CAL-27 cells are widely used in oral cancer research to study tumor growth, invasion, and drug resistance, providing a clinically relevant platform for studying MYG1-mediated mitochondrial pathways.
MYG1 encodes a mitochondrial 3??-5?? exoribonuclease essential for processing mitochondrial RNA and facilitating ribosome assembly, thereby enabling translation of oxidative phosphorylation (OXPHOS) complex subunits. It operates in a network with PNPT1, a key mitochondrial RNA processing enzyme, and interacts with mitochondrial ribosomal proteins and the MTERF family of transcription regulators. Upstream, MYG1 expression is controlled by metabolic and stress signals involving NRF1, TFAM, and TP53; downstream, its activity generates mitochondrial RNA degradation intermediates and influences levels of OXPHOS components, linking mitochondrial gene expression to energy production.
In the CAL-27 context, MYG1 knockout impairs mitochondrial translation, resulting in defective OXPHOS complexes, diminished respiratory capacity, and elevated reactive oxygen species. Coupled with mutant p53, this metabolic crisis activates apoptotic pathways and reduces proliferative and migratory capabilities. The model thus provides a dedicated tool to dissect how mitochondrial exonuclease activity intersects with tumor cell fitness, survival signaling, and stress responses??mechanisms increasingly recognized in oral carcinogenesis.
These polyclonal knockout cells are ideally suited for population-level analyses, including Seahorse respirometry to measure oxygen consumption, Annexin V flow cytometry for apoptosis detection, and transwell invasion assays. Additional applications include quantifying mitochondrial RNA intermediates via RT-qPCR, profiling OXPHOS proteins by immunoblotting, and co-immunoprecipitating MYG1 interactors such as PNPT1. The model also supports drug screening to assess how mitochondrial dysfunction alters chemosensitivity in oral cancer. For further details and technical support, please contact Ascent Research.
